Literature DB >> 1829751

Quantification of apo[a] and apoB in human atherosclerotic lesions.

J M Pepin1, J A O'Neil, H F Hoff.   

Abstract

Lipoprotein[a] or Lp[a] is a cholesterol-rich plasma lipoprotein that is associated with increased risk for cardiovascular disease. To better understand this association we determined the amount of apo[a] and apoB as possible estimates for Lp[a] and low density lipoprotein (LDL) accumulation in atherosclerotic lesions and in plasma, from patients undergoing vascular surgery, using specific radioimmunoassays for apolipoprotein[a] and apolipoprotein B. Apo[a] and apoB were operationally divided into a loosely bound fraction obtained by extracting minced samples of plaque with phosphate-buffered saline (PBS), and a tightly bound fraction obtained by extracting the residual tissue with 6 M guanidine-HCl (GuHCl). We found that 83% of all apo[a] but only 32% of all apoB in lesions was in the tightly bound fraction. When normalized for corresponding plasma levels, apo[a] accumulation in plaques was more than twice that of apoB. All fractions of tissue apo[a], loosely bound, tightly bound, and total, correlated significantly with plasma apo[a]. However, no significant correlations were found between any of the tissue fractions and plasma apoB. If all apo[a] and apoB had been associated with intact Lp[a] or LDL particles, the calculated mass of tightly bound Lp[a] would actually have exceeded that of tightly bound LDL in five cases with plasma Lp[a] levels above 5 mg apo[a] protein/dl. When PBS and GuHCl extracts of lesions were subjected to one-dimensional electrophoresis, the major band stained for lipid and immunoblotted positively for apo[a] and apoB, suggesting the presence of some intact Lp[a] in these extracts. These results suggest that Lp[a] accumulates preferentially to LDL in plaques, and that plaque apo[a] is directly associated with plasma apo[a] levels and is in a form that is less easily removable than most of the apoB. This preferential accumulation of apo[a] as a tightly bound fraction in lesions, could be responsible for the independent association of Lp[a] with cardiovascular disease in humans.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1829751

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  18 in total

Review 1.  Lipoprotein(a): its inheritance and molecular basis of its atherothrombotic role.

Authors:  A M Scanu
Journal:  Mol Cell Biochem       Date:  1992-08-18       Impact factor: 3.396

2.  Evidence that the fibrinogen binding domain of Apo(a) is outside the lysine binding site of kringle IV-10: a study involving naturally occurring lysine binding defective lipoprotein(a) phenotypes.

Authors:  O Klezovitch; C Edelstein; A M Scanu
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

Review 3.  Lipoprotein(a): searching for a function.

Authors:  P C Harpel; M Poon; X Zhang; M B Taubman
Journal:  Trans Am Clin Climatol Assoc       Date:  1996

4.  Subendothelial retention of lipoprotein (a). Evidence that reduced heparan sulfate promotes lipoprotein binding to subendothelial matrix.

Authors:  S Pillarisetti; L Paka; J C Obunike; L Berglund; I J Goldberg
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

5.  Immunopathology of desialylation: human plasma lipoprotein(a) and circulating anti-carbohydrate antibodies form immune complexes that recognize host cells.

Authors:  P S Sabarinath; P S Appukuttan
Journal:  Mol Cell Biochem       Date:  2015-01-30       Impact factor: 3.396

6.  Circulating Lp(a):LDL complexes contain LDL molecules proportionate to Lp(a) size and bind to galectin-1: a possible route for LDL entry into cells.

Authors:  Vasantha Kalaivani; Padinjaradath Sankunni Appukuttan
Journal:  Lipids       Date:  2014-08-21       Impact factor: 1.880

7.  Enhanced macrophage uptake of lipoprotein(a) after Ca2+-induced aggregate-formation.

Authors:  S Tanaka; A Yashiro; H Tasaki; Y Nakashima
Journal:  Lipids       Date:  1998-04       Impact factor: 1.880

8.  Plasma anti-α-galactoside antibody mediates lipoprotein(a) binding to macrophages.

Authors:  Binu Sheela; Genu George; Geetha Mandagini; Padinjaradath S Appukuttan
Journal:  Glycoconj J       Date:  2016-08-19       Impact factor: 2.916

9.  Lipoprotein(a) vascular accumulation in mice. In vivo analysis of the role of lysine binding sites using recombinant adenovirus.

Authors:  S D Hughes; X J Lou; S Ighani; J Verstuyft; D J Grainger; R M Lawn; E M Rubin
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

10.  Lp(a)/apo(a) modulate MMP-9 activation and neutrophil cytokines in vivo in inflammation to regulate leukocyte recruitment.

Authors:  Menggui Huang; Yanqing Gong; Jessica Grondolsky; Jane Hoover-Plow
Journal:  Am J Pathol       Date:  2014-03-17       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.